
$9.3 million award to boost nanotech vaccine research
Michigan Nanotechnology Institute and NanoBio Corporation to work in tandem to test nanoemulsion-based vaccines against common diseases
Meet the expert:
James R. Baker, Jr. M.D.
Learn more:
Michigan Nanotechnology Institute
ANN ARBOR, Mich. - University of Michigan efforts to develop new nanoemulsion-based vaccines for a variety of diseases will move forward much more quickly thanks to a large federal award.
The National Institute of Allergy and Infectious Diseases has awarded U-M a contract for $9,340,522 over five years. Of that total, $5,224,548 will fund research at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at U-M (MNIMBS), and $4,115,974 will fund work at Ann Arbor-based NanoBio Corporation, the institute’s research partner for the project.
"This contract allows us to develop the process to apply our nanoemulsion technology to almost any form of antigen. We believe this will facilitate a number of new vaccines as well as improve existing vaccines," says James R. Baker Jr., M.D., the grant’s principal investigator, director of the Michigan Nanotechnology Institute, and Ruth Dow Doan Professor of Internal Medicine at U-M. He is also founder and CEO of NanoBio Corporation, in which he holds a financial interest.
A nanoemulsion vaccine consists of a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The nanoemulsion acts as an adjuvant, an ingredient in most vaccines that enhances the immune response to the weakened or partial pathogen.
Nanoemulsions, a technology developed and patented by U-M and licensed to NanoBio Corporation, have proved to be effective adjuvants.
In a number of previous preclinical studies at U-M, nanoemulsion-based vaccines, which are given in the nose, proved non-toxic and produced strong immunity against influenza, anthrax, smallpox, HIV and hepatitis B. NanoBio Corp. is currently conducting a Phase I clinical trial of a nanoemulsion-based intranasal vaccine for influenza.
The new research aims to discover how specific nanoemulsion formulations act upon certain receptors on cells that play key roles in innate immunity, a crucial first line of defense against invading pathogens. As part of its subcontract, NanoBio Corporation will develop large numbers of nanoemulsion formulations to be tested for their immunity-producing capacity in different disease models.
Later stages of the U-M research will include preclinical testing of adjuvant candidates in laboratory studies with human cells, followed by animal studies using the best candidates.
Other U-M scientists who will be involved in the new research include co-investigators Douglas Smith, Ph.D., and Anna U. Bielinska, Ph.D., both research assistant professors in the department of internal medicine and the Michigan Nanotechnology Institute.
Pyramids and Lasers Chess Game
No comments:
Post a Comment